Click here for Products

Company news

Home > News > Company news

Nirmidas Biotech Receives FDA Emergency Use Authorization for its COVID-19 Rapid Antibody Fingerstick Test

01-05-2021

Click Here for News on Businesswire Click Here for News on 360 DX

Learn More about MidaSpot™ COVID-19 Antibody Combo Detection Kit

How to Purchase MdiaSpot™ COVID-19 Antibody Combo Detection Kit

FDA Emergency Use Authorization can be viewed/downloaded here

NEXT: Nirmidas Has Obtained 12-Month Shelf Life for MidaSpot® COVID-19 Antibody Combo Detection Kit

PREVIOUS: Nirmdas Has Developed High-Accuracy pGOLD™ Microarray Based High Throughput ELISA-like COVID-19 IgG/IgM/IgA Assay for Research Use Only

Privacy Policy© 2021-2024 Nirmidas Biotech, Inc., 319 N. Bernardo Ave, Mountain View, CA, 94043, USA info@nirmidas.com